推荐应用
Lomvastomig 是一种抗 PDCD1/HAVCR2 的人源 IgG1 κ 单克隆抗体。Lomvastomig 的同型对照产品:Human IgG1 kappa, Isotype Control。
For Powder, reconstitute with sterile, distilled water to a final concentration of 1 mg/ml. Gently shake to solubilize completely. Do not vortex.
本产品仅用作科学研究!
The detected molecular weight of Anti-PD-1 & TIM-3 Reference Antibody (Lomvastomig) is 145.11 kDa.
Anti-PD-1 & TIM-3 Reference Antibody (Lomvastomig) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.
The purity of Anti-PD-1 & TIM-3 Reference Antibody (Lomvastomig) is 90.00%, determined by SEC-HPLC.
Lomvastomig bound to PD-1 protein, and then rebounded to secondary antibodies(Anti-human-IgG-Fc-HRP) , and read OD450. As shown in fig, Lomvastomig bound to hu-PD-1-His, and the EC50 was 0.014 nM.
Lomvastomig bound to TIM-3 protein, and then rebounded to secondary antibodies(Anti-human-IgG-Fc-HRP) , and read OD450. As shown in fig, Lomvastomig bound to hu-TIM-3-His, and the EC50 was 0.933 nM.
Lomvastomig bound to huPD-1-Jurkat cells, and then rebounded to fluorescent secondary antibodies(Anti-human IgG, Fcγ PE) , and test by flow cytometry. As shown in fig, Lomvastomig bound to huPD-1-Jurkat cells, and the EC50 was 1.788 nM.
Lomvastomig bound to huTIM3-FL-HEK293 cells, and then rebounded to fluorescent secondary antibodies(Anti-human IgG, Fcγ PE) , and test by flow cytometry. As shown in fig, Lomvastomig bound to huTIM3-FL-HEK293 cells, and the EC50 was 239.100 nM.
Co-incubation of Lomvastomig with PD-1-NF-AT-Jurkat and CD3L-huPD-L1-CHO-K cells and incubated for 6 hours. Bright-Lite was used to detect the fluorescent signal. As shown in fig, Lomvastomig was able to block the PD-1/PD-L1 signaling pathway, and the EC50 was 4.300 nM.
-80°C for 2 years under sterile conditions;-20°C for 1 year under sterile conditions;Avoid repeated freeze-thaw cycles.
【应用方向】单细胞表观测序中的抗体应用
307
2026-07-29
【应用案例】细胞内蛋白流式细胞术protocol(甲醇方法)
723
2026-08-03
【选购指南】类器官研究之构建与起始细胞鉴定抗体推荐
686
2026-07-21
【选购指南】类器官研究之功能成熟度评估抗体推荐
517
2026-07-21
【应用方向】趋化因子信号传导通路——身体“信号导航”解析
524
2026-07-21
【选购指南】重度抑郁症(MDD)通路研究抗体推荐
501
2026-07-21
【选购指南】帕金森病(PD)代谢机制核心抗体研究指南
512
2026-07-21
【应用方向】抗体助力心脏免疫研究——解锁心衰防治新方向
454
2026-07-21
【应用方向】抗体助力心肌肥大与心衰研究:从基础探索到科研应用
484
2026-07-21
【应用方向】抗体助力癌症代谢通路研究——肿瘤代谢科普与研究工具指南
533
2026-07-21
【应用方向】造血干细胞研究相关抗体选型与推荐
18445
2026-04-14
【应用方向】间充质干细胞(MSC)应用研究抗体推荐—用于表型表征、机制研究与分化评估的常用靶标与抗体选型参考
20624
2026-04-14
【应用方向】抗体应用研究—细胞死亡
20465
2026-07-16
【应用方向】Anti-B7-H3/CD276:不只是免疫checkpoint,更是肿瘤进展的“助推器”
18542
2026-02-05
【前沿资讯】上新 | 抗Payload抗体,助力ADC药物动力学分析
19838
2024-07-17





